ANNOUNCEMENT 20 Mar 2020

On 20 March 2020, the UK authorities announced the introduction of an export ban on 82 difference pharmaceutical-related goods due to anticipated shortages in the country following the COVID-19 outbreak.

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

The UK Government, Medicines that cannot be parallel exported from the UK - Guidance, Published on 3 October 2019: https://www.gov.uk/government/publications/medicines-that-cannot-be-parallel-exported-from-the-uk
The UK Government, List of medicines that cannot be parallel exported from the UK, last updated 20 March 2020: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/874142/Medicines_that_cannot_be_parallel_exported_from_the_UK_20_March.csv/preview
The UK Government, Department of Health and Social Care, press release of 20 March 2020, Crucial medicines protected for coronavirus (COVID-19) patients: https://www.gov.uk/government/news/crucial-medicines-protected-for-coronavirus-covid-19-patients

Inception date: 21 Mar 2020 | Removal date: open ended
Still in force

Export ban

On 21 March 2020, the Department of Health and Social Care of the United Kingdom added 82 goods to the medicines that cannot be parallel exported from the UK list. The export ban was introduced on the subject goods due to anticipated shortages in the country in response to the COVID-19 outbreak. The among the medicines that cannot be parallel exported from the UK list are adrenaline, insulin, ketamine, paracetamol and morphine.

In this context, the UK authorities noted in a press release that: "All medicines on the list are in high demand across Europe as health systems come under increasing pressure from coronavirus (COVID-19). The restrictions are a standard measure to manage potential medicine shortages and protects UK patients by ensuring the NHS has the treatments to continue providing world-class care. Companies that parallel export a medicine on the ban list may face tough enforcement action from the Medicines and Healthcare products Regulatory Agency (MHRA) and risk having their trading licence revoked for serious breaches."

Additionally, the UK Minister of Health Lord Bethell stated: "We are today banning the parallel export of more than 80 crucial medicines to protect patients in the UK and help ensure they can always get the treatments they need"

The UK authorities noted that: "Parallel export of a medicine on the list (ed. medicines that cannot be parallel exported from the UK list) is considered a breach of regulation 43(2) of the Human Medicines Regulations 2012 and a contravention of the wholesale dealer licence and may lead to regulatory action by the Medicines and Healthcare products Regulatory Agency (MHRA), which could include immediate suspension of the wholesale dealer licence."

AFFECTED SECTORS